Comparative effects of semaglutide tirzepatide and retatrutide on renal fibrosis in UUO and aged mice.
Key claim: In non-diabetic UUO and aged-mouse models, semaglutide, tirzepatide, and retatrutide reduced renal fibrosis via distinct pathway patterns, with retatrutide showing the greatest efficacy at the doses tested.
Abstract
Chronic kidney disease is a major health burden. Given the therapeutic potential of GLP-1 receptor agonists (semaglutide, tirzepatide, and retatrutide) in diabetic nephropathy, we evaluated their anti-fibrotic and anti-inflammatory effects in non-diabetic renal fibrosis using HK-2 cells and murine UUO and aging models. Integratinganddata showed model- and drug-specific patterns of action among the three agents. In the UUO model, semaglutide effects were associated with PI3K-AKT inhibition, tirzepatide effects with PI3K-AKT inhibition and PPAR pathway activation, and retatrutide effects with concurrent inhibition of both PI3K-AKT and NF-κB pathways. In the aging model, all three drugs were linked to G/M arrest mitigation. Retatrutide showed the greatest efficacy at the doses tested in the models studied. This comparative study offers a framework for understanding the renoprotective actions of these drugs and generates hypotheses for future investigation.
Why this matters
Kidney fibrosis is a core aging pathology, and this study extends the incretin-class story beyond metabolic endpoints into a direct organ-aging model, with retatrutide (a GLP-1/GIP/glucagon triple agonist) outperforming semaglutide and tirzepatide preclinically. It sharpens the mechanistic case that these drugs act on aging-relevant pathways independent of diabetes, while leaving the human question — whether renal or broader healthspan benefits translate — entirely open.